Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

JAM-A as a Prognostic Factor and New Therapeutic Target in Multiple Myeloma

Antonio Solimando, MD, Andreas Brandl, PhD, Mattenheimer Katharina, Carolin Graf, Miriram Ritz, Anna Ruckdeschel, Thorsten Stühmer, PhD, Martina Rudelius, MD, Maria Antonia Frassanito, PhD, Rosenwald Andreas, MD, Franz Jakob, MD, Angelo Vacca, MD, Hermann Einsele, MD, Andreas Beilhack, MD

Blood (2016) 128 (22): 307.

https://doi.org/10.1182/blood.V128.22.307.307

Published: 2016

Journal Articles

Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8 + T-cell killing

Patrizia Leone, Simona Berardi, Maria Antonia Frassanito, Roberto Ria, Valli De Re, Sebastiano Cicco, Stefano Battaglia, Paolo Ditonno, Franco Dammacco, Angelo Vacca, Vito Racanelli

Blood (2015) 126 (12): 1443–1451.

https://doi.org/10.1182/blood-2015-01-623975

Published: 2015

Journal Articles

Cancer Associated Fibroblasts in Multiple Myeloma: The Urokinase Receptor System in Tumor Growth Regulation

Simona Serratì, Carla Minoia, Anastasia Chilla, Anna Laurenzana, Francesca Margheri, Maria Antonia Frassanito, Nicola Sgherza, Giacoma De Tullio, Angelo Vacca, MD PhD, Pasquale Iacopino, MD, Mario Del Rosso, Gabriella Fibbi, Attilio Guarini

Blood (2014) 124 (21): 5687.

https://doi.org/10.1182/blood.V124.21.5687.5687

Published: 2014

Journal Articles

Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8 + T cells and characterize the progression of MGUS to multiple myeloma

Vito Racanelli, Patrizia Leone, Maria Antonia Frassanito, Claudia Brunetti, Federico Perosa, Soldano Ferrone, Franco Dammacco

Blood (2010) 115 (6): 1185–1193.

https://doi.org/10.1182/blood-2009-06-228676

Published: 2010

Includes: Supplemental data

Journal Articles

Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis

Maria Antonia Frassanito, Antonio Cusmai, Giuseppe Iodice, Franco Dammacco

Blood (2001) 97 (2): 483–489.

https://doi.org/10.1182/blood.V97.2.483

Published: 2001

NARROW

JAM-A as a Prognostic Factor and New Therapeutic Target in Multiple Myeloma

Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8 + T-cell killing

Cancer Associated Fibroblasts in Multiple Myeloma: The Urokinase Receptor System in Tumor Growth Regulation

Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8 + T cells and characterize the progression of MGUS to multiple myeloma

Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis

Email alerts

ASH Publications

American Society of Hematology

JAM-A as a Prognostic Factor and New Therapeutic Target in Multiple Myeloma

Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8 + T-cell killing

Cancer Associated Fibroblasts in Multiple Myeloma: The Urokinase Receptor System in Tumor Growth Regulation

Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8 + T cells and characterize the progression of MGUS to multiple myeloma

Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only